|
|
 |
| |
|
Home > Drug Companies > Cell Therapeutics, Inc.
Cell Therapeutics, Inc.
Established in September 1991, they currently have facilities and staff in the U.S. and Europe. Their corporate headquarters are in Seattle, Washington with research and development facilities in Bresso, Italy.
Cell Therapeutics, Inc. supports their committed professionals with state of the art facilities and laboratories. They recognize the value of each of their employees and take pride in creating a positive work environment. Their strength lies in the individuals who work to accomplish their collective goals. Board of Directors are James A. Bianco, M.D. CTI principal founder, President and CEO.
Cell Therapeutics, Inc. licensed the worldwide exclusive rights to polyglutamate and related polymers and their applications from PG TXL Company in 1998. The technology was originally developed at the M.D. Anderson Cancer Center. The initial patent, which issued in November 1999, covers polyglutamate and related polymers coupled with commonly used cancer drugs such as paclitaxel, docetaxel, etoposide, teniposide, or camptothecins. The patented technology covers formulations of polyglutamate conjugated paclitaxel that also include the use of human serum albumin and conjugation to epothilones.
As CTI's cancer drugs progress through clinical trials to commercialization, their commitment to patients and the real issues of their cancer treatments grows stronger. The challenge to overcome the therapeutic limitations of cancer treatment provides them with a focus and sense of urgency.
Cell Therapeutics, Inc. are developing a new way to deliver cancer drugs more selectively to tumor tissue to reduce the toxic side effects to normal organs and tissues and to improve the anti tumor activity of existing chemotherapy agents.
CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In their pursuit of making cancer more treatable, the Company is developing a diversified portfolio of oncology products focused on identifying new, less toxic, and more effective cancer therapies.
Back to Drug Companies
|
|
|
|
|
|
|
|